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Available online 13 April 2016Cranial malformations are a signiﬁcant cause of perinatal morbidity andmortality. Iroquois homeobox transcrip-
tion factors (IRX) are expressed early in bone tissue formation and facilitate patterning andmineralization of the
skeleton. Mice lacking Irx5 appear grossly normal, suggesting that redundancy within the Iroquois family.
However, global loss of both Irx3 and Irx5 in mice leads to signiﬁcant skeletal malformations and embryonic
lethality from cardiac defects. Here, we study the bone-speciﬁc functions of Irx3 and Irx5 using Osx-Cre to drive
osteoblast lineage–speciﬁc deletion of Irx3 in Irx5−/− mice. Although we found that the Osx-Cre transgene
alone could also affect craniofacial mineralization, newborn Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice displayed
additional mineralization defects in parietal, interparietal, and frontal bones with enlarged sutures and reduced
calvarial expression of osteogenic genes. Newborn endochondral long bones were largely unaffected, but we
observed marked reductions in 3–4-week old bone mineral content of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice. Our
ﬁndings indicate that IRX3 and IRX5 can work together to regulate mineralization of speciﬁc cranial bones. Our
results also provide insight into the causes of the skeletal changes and mineralization defects seen in Hamamy
syndrome patients carrying mutations in IRX5.





Craniofacial development requires tight coordination of cell migra-
tion, proliferation, and mineralization of osteogenic lineages (Wilkie &
Morriss-Kay, 2001; Franz-Odendaal, 2011). Osteoblast dysfunction is
thought to be a major contributor to diseases that affect craniofacial
bones andmineralization (Rice, 2008). The complex genetic and spatial
interactions that occur during craniofacial development pose major
challenges to understanding mineralization during the development
of the skull.Francisco, 513 Parnassus Ave.,
. This is an open access article underIroquois homeobox domain transcription factors (IRX) are highly
conserved proteins that regulate neural, cardiac, and bone develop-
ment (Kerner et al., 2009; Cavodeassi et al., 2001; Kim et al., 2012;
Li et al., 2014). IRX proteins all contain two highly conserved do-
mains. The homeodomain is postulated to regulate interactions be-
tween transcriptional regulators by binding to genomic regions to
regulate target gene expression, and the IRO Box is involved in
protein-protein binding (Cavodeassi et al., 2001; Hiroi et al., 2001).
Six IRX transcription factors have been identiﬁed (IRX1-IRX6), of
which Irx1, Irx2, and Irx4 cluster to chromosome 5 in humans (chro-
mosome 13 in mice) and Irx3, Irx5, and Irx6 cluster to chromosome
16 (chromosome 8 in mice) (Gaborit et al., 2012; Houweling et al.,
2001). Irx3 and Irx5 expression is strikingly similar in developing
mouse tissues (Houweling et al., 2001).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tissues. Irx1 is important for the speciﬁcation of individual placodes
through BMP signaling (Glavic et al., 2004). IRX3 has been shown to
bind to the Bmp10promoter,which is important for ventricular septation,
while IRX5 can bind to GATA3 and TRPS1 to regulate CXCL12 during bone
progenitor migration in Xenopus embryos (Gaborit et al., 2012; Bonnard
et al., 2012). Irx1 and Irx2 have been shown to regulate vertebrate digit
formation,while Irx3and Irx5mediate earlymouse limbbud speciﬁcation
by regulating Gli3 expression (Li et al., 2014; Becker et al., 2001;
McDonald et al., 2010). Surprisingly, loss of Irx5 alone leads to a grossly
normal mouse (Gaborit et al., 2012), while loss of both Irx3 and Irx5 to-
gether result in an embryonic lethal phenotype from cardiac defects
and skeletal malformations (Li et al., 2014; Gaborit et al., 2012). Unfortu-
nately, the early embryonic lethality of Irx3−/−/Irx5−/−mice contributes
to our incomplete understanding of the role of Irx3 and Irx5 in osteoblast
function (Li et al., 2014; Gaborit et al., 2012).
Twomutations in human IRX5, Ala150Pro andAsn166Lys occur in pa-
tients with Hamamy syndrome (OMIM MIM611174; Bonnard et al.,
2012), who present with craniofacial dysmorphism, osteopenia, tooth
eruption defects, and hip dysplasia, alongwith cardiac defects andmicro-
cytic hypochromic anemia (Bonnard et al., 2012; Hamamy et al., 2007a,
2007b). The function of IRX5 seems to differ in mice and humans as the
human phenotype is not observed in Irx5−/− mice (Costantini et al.,
2005). Iroquois homeodomains helix two and helix three are completely
conserved in IRX1-IRX6 (Bonnard et al., 2012). The Hamamy mutations
Ala150Pro andAsn166Lys occur in the IRX5helix twoor three respective-
ly, indicating the importance of these residues in IRXhomeodomain func-
tion. Irx5 was previously shown to form homodimers and heterodimers
with Irx3 and Irx4 in transfected 10T1/2 cells (He et al., 2009). Previous
meta-analysis of IRX3, IRX5, GATA3, and TRPS1 also indicated these pro-
teins were involved in a regulatory network (Bonnard et al., 2012). Inter-
estingly, patients with a 3.2 Mb deletion at 16q12.2–13, which includes
IRX3, IRX5, and IRX6, show similar craniofacial features to those of
Hamamy patients (Bonnard et al., 2012; Chang et al., 2010).
Irx3−/− and Irx5−/− mice do not show any Hamamy syndrome
characteristics (Costantini et al., 2005; Smemo et al., 2014), but several
aspects of the Hamamy syndrome phenotype are recapitulated in Irx3
and Irx5 double knockout mice (Irx3−/−/Irx5−/− mice), including the
cardiac defects and craniofacial dysmorphisms (Hiroi et al., 2001).
Furthermore, the hind limb skeletal hypoplasia reported in Irx3−/−/
Irx5−/−mouse embryos and the femoral fragility observed in Hamamy
syndrome patients suggest that IRX3 and IRX5 are important for limb
development in vertebrates (Gaborit et al., 2012; Hamamy et al.,
2007a). Although the Irx3−/−/Irx5−/− mice have a complete loss of
protein in comparison to the point mutations found in humans with
Hamamy syndrome, the ﬁnding that multiple features of Hamamy
syndrome phenotype are recapitulated in Irx3−/−/Irx5−/− mice indi-
cates that this mouse model may be useful for understanding the role
of Iroquois proteins in vivo. Here, we avoid the embryonic lethality
from cardiac malformations in Irx3−/−/Irx5−/−mice by using the Osx-
Cre transgene (Rodda & McMahon, 2006) to drive osteoblast-speciﬁc
deletion of Irx3 in Irx5−/−mice.
2. Results
2.1. Body size and craniofacial bonemineralization are reduced in newborn
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice
We focused our studies on newborn Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+
mice (Supplementary Fig. 1A) to understand the role of Irx3 and Irx5
in early bone mineralization. The allelic separation of Irx3 and Irx5 was
a rare event (approximately 0.5–2%, Supplementary Fig. 1B) and
thus single allele mice were excluded from further analysis. Newborn
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice appeared grossly normal but slightly
smaller than control littermates (Fig. 1A). 43% of Irx3ﬂox/ﬂox/Irx5−/−/
Osx-Cre+ were viable at birth, which appeared to be an effect of theOsx-Cre allele as Irx3+/+/Irx5+/+/Osx-Cre+ also showed similar
decreased neonatal viability (Supplementary Fig. 1C). However,
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice rarely survived to 4 weeks of age.
This early lethality was not observed in 3–4-week-old Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre− mice (Supplementary Fig. 1D) suggesting that the
loss of Irx3 and Irx5 contributed to this decrease in survival in the
neonatal stage. We observed small but statistically signiﬁcant reduc-
tions in newborn total body weight and length in mice with a loss of
Irx5 independent of Osx-Cre expression (Fig. 1B, C and Supplementary
Fig. 2A and B). Lower limbs of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ assessed by
Dual energy X-ray absorptiometry (DEXA) showed no differences in
bone mineral density (Fig. 1D and Supplementary Fig. 2C). These data
indicate that global deletion of Irx5 alone was sufﬁcient to affect body
size, but that additional deletion of Irx3 in osteoblastic cells did not
have further effects on body size.
During the course of our studies, it became evident that Irx3+/+/
Irx5+/+/Osx-Cre+mice had an unexpected basal phenotypewith reduc-
tions in themineralized area of the frontal bone. This was conﬁrmed by
recent reports of effects by the Osx-Cre transgene alone on craniofacial
mineralization (Wang et al., 2015; Huang & Olsen, 2015). Micro-
computed tomography (microCT) 3D image reconstruction showed
both Irx3+/ﬂox/Irx5+/−/Osx-Cre+ and Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice
had reduced mineralization in the frontal, parietal, and interparietal
bones (Fig. 2 and Supplementary Figs. 2D, E, and 3). The long bones
from both Irx3+/ﬂox/Irx5+/−/Osx-Cre+ and Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+
newborn mice also appeared unaffected by microCT.
We next performed whole body skeletal staining of newborn
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice with alizarin red and alcian blue.
Irx3+/ﬂox/Irx5+/−/Osx-Cre+ and Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice
showed reduced mineralization in frontal, parietal, and interparietal
bones (Fig. 3A and 3B).Wemeasured the frontal bone total mineralized
area, using the orbits as landmarks; the suture width in the same area;
the length of the parietal and frontal bones along the suture; and the
interparietal bonewidth (Fig. 3C). As noted above, we found reductions
in the mineralized area of the frontal bone in Irx3+/+/Irx5+/+/Osx-Cre+
mice; however, Irx3+/ﬂox/Irx5+/−/Osx-Cre+ and Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre+ mice showed an even greater reduction in frontal bone minerali-
zation (Fig. 3D and Supplementary Fig. 2F-I). Additionally, the width
of the suture was signiﬁcantly greater in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−
mice than in Irx3+/+/Irx5+/+/Osx-Cre+ and wildtype mice (Fig. 3E and
F). The parietal and frontal bone total length showed a reduction caused
by the Osx-Cre but not with Irx3 or Irx5 loss (Fig. 3G). We noted no sig-
niﬁcant differences between Irx3+/ﬂox/Irx5+/−/Osx-Cre− and Irx3+/ﬂox/
Irx5+/−/Osx-Cre+ mouse cranial measurements (Supplementary
Fig. 2F-L). These data indicate that the presence of the Osx-Cre trans-
gene alone can reduce cranial mineralization, but the absence of Irx3
and Irx5 in osteoblastic cells leads to a greater reduction in bone
mineralization.2.2. Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ skulls have reduced osteoblastic
mineralization
We next used hematoxylin and eosin staining to identify alterations
to the bone architecture and mineralization in Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre+ mice. We found that bone accumulation was less in Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre+ mice in the parietal and interparietal bones than in
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre− mice (Fig. 4A). Closer inspection of the
frontal, parietal, and interparietal bones revealed a reduction in the
thickness of mineralized bone in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice
with nomajor change in cuboidal osteoblasts adjacent to bony surfaces
(Fig. 4B, green arrows). Occipital bones showed no signiﬁcant
differences among the genotypes (data not shown). These histological
analyses suggest that there is not a major change in osteoblasts mor-
phology and numbers at the bone surfaces, but decreased osteoblast
mineralization caused by loss of Irx3 and Irx5.
Fig. 1. Osteoblastic speciﬁc deletion of Irx3 in newborn Irx5−/−mice results in smaller mice. (A) Representative photos of newborn mice. (B) Newborn total body weight, (C) newborn
body length, and (D) newborn BMD of lower right limb of indicated genotypes. Data are from n = 16 Irx3+/+/Irx5+/+/Osx-Cre−, n= 5 Irx3+/+/Irx5+/+/Osx-Cre+, n= 27 Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre−, n = 9 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ for body weight and length measurements. For BMD, n = 3 Irx3+/+/Irx5+/+/Osx-Cre−, n = 3 Irx3+/+/Irx5+/+/Osx-Cre+, n = 3
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−, n= 3 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+. Statistical differences were determined by a Student's t-test, *p b 0.05, **p b 0.01, ***p b 0.001. N.S., not signiﬁcant.
88 C.J. Cain et al. / Bone Reports 5 (2016) 86–952.3. Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ skulls have reduced expression of genes
that regulate osteoblastic mineralization
We next examined whole calvarial expression of genes involved in
osteoblast mineralization and maturation. Early markers of osteoblastFig. 2. Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice have reduced skull mineralization. Representative sku
(A) Right lateral view of the skull. (B) Posterior view of the skull. Green arrows denote the
frontal bones. Images are representative of n= 2 of each genotype.lineage speciﬁcation such as Runx2 (Fig. 5A) and Osx (Fig. 5B) were not
signiﬁcantly altered; however, the mature osteoblast markers Col1a1
(Fig. 5C) and Osteocalcin (Bglap) (Fig. 5D) were signiﬁcantly reduced in
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ calvaria, even in relation to the reductions
in Bglap expression in Irx3+/+/Irx5+/+/Osx-Cre+ and Irx3ﬂox/ﬂox/Irx5−/−/ll microCT imaging of newborn Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ and control littermate skulls.
interparietal bone, red arrows denote the parietal bones, and yellow arrows denote the
Fig. 3. Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ display reducedmineralization in frontal, parietal, and interparietal bones. (A) Left lateral view and (B) superior view of representative alizarin red and
alcian blue stained newbornmice. Green arrows denote the interparietal bone, red arrows denote theparietal bones, and purple arrows denote the frontal bones. (C) Superior view images
were measured for (D) the width of mineralized frontal bone, (E) sagittal suture width, (F) suture width divided by the width between the eye sockets, and (G) length of the frontal and
parietal bones, measured along the sagittal suture. Photos and measurements are from n= 5 Irx3+/+/Irx5+/+/Osx-Cre−, n= 4 Irx3+/+/Irx5+/+/Osx-Cre+, n= 7 Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre−, n= 6 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+. Statistical differences were determined by a Student's t-test, *p b 0.05, **p b 0.01, ***p b 0.001. N.S., not signiﬁcant.
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eralization, were not changed in expression in Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre+ calvaria (data not shown).
We next examined calvarial gene expression of chondrogenesis
using Sox9, Col2a1, Acan, and Mmp9, since mesenchymal cells from
intermembranous bones maintain chondrogenic gene expression
(Aberg et al., 2005). There were no observable differences in Sox9
(Fig. 5E) and Col2a1 (Fig. 5F) levels, although we observed signiﬁcant
reductions of Acan (Fig. 5G) in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre− calvaria
that were not present in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ calvaria. We ob-
served a signiﬁcant reduction in Mmp9 expression in Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre+ calvaria that was not observed in the other geno-
types, even though Irx3+/+/Irx5+/+/Osx-Cre+ and Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre− calvaria were modestly reduced in Mmp9 expression (Fig.
5H). We observed no differences in expression of apoptosis related
genes Bcl2 and Bcl-xl in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ calvaria (Fig. 5I-J).
This indicated that loss of Irx3 and Irx5 together in osteoblastic lineage
cells affects later osteogenic genes more signiﬁcantly than chondrocyte
genes and does not result in increased apoptosis of osteogenic cells in
the calvaria.
In studies usingXenopus laevis embryos, IRX5 interactedwithGATA3
and TRPS1, forming a complex that down regulated CXCL12 production
(Bonnard et al., 2012), although IRX3 and IRX5did not directly inﬂuence
Gata3 transcription (data not shown). We examined the expression of
Cxcl12 and Trps1 in order to determine if the reduced bone mineraliza-
tion in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice was through downstream
Fig. 4. Osteoblastic bone mineralization is reduced in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ skulls. (A) Representative sagittal sections of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre− and Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre+ skulls stained with hematoxylin and eosin. Frontal, parietal, and interparietal bones are shown in the boxes and taken at higher magniﬁcation to observe cellular morphology.
(B) Irx3+/+/Irx5+/+/Osx-Cre−, Irx3+/+/Irx5+/+/Osx-Cre+, Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−, and Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ enlarged photos of frontal, parietal, interparietal, and occipital
bones. Green arrows denote regions with mineralized bone in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice and control littermates. Data is representative n= 3 Irx3+/+/Irx5+/+/Osx-Cre−, n= 3
Irx3+/+/Irx5+/+/Osx-Cre+, n= 5 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−, n= 4 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+.
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ly altered in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice (Fig. 5K). Interestingly,
there was a signiﬁcant reduction in Trps1 in Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre+ calvaria (Fig. 5L), a gene that can reduce Bglap expression in vitro
and is required for proper osteoblast mineralization (Piscopo et al.,
2009; Kuzynski et al., 2014). These ﬁndings suggest a role for Irx3 and
Irx5 in the regulation osteoblast mineralization gene expression and
suggest that in mineralization, Irx3 and Irx5 may function through a
pathway that is distinct from Gata3.
2.4. Older Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice have reduced bone
mineralization
Wenext looked atwhole body and skeletal mineralization of Irx3ﬂox/
ﬂox/Irx5−/−/Osx-Cre+mice that survived to 3–4 weeks of age to identify
if there were similar reductions in bone mineralization described in
Hammy patients (Hamamy et al., 2007a). 3–4-week-old Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre+ mice had signiﬁcant reductions in body size and
length (Fig. 6A-C), while body weights remained comparable in all the
other genotypes through 12weeks of age,with the exception of a signif-
icant decrease in bodyweight in 12week old Irx3+/ﬂox/Irx5+/−/Osx-Cre+
mice (Fig. 6D-E). Alizarin red and alcian blue staining of 3–4-week-old
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice revealed an overall reduction bonemineralization with gross skeletal abnormalities and spontaneous frac-
tures in 3 out of the 10 mice that were analyzed (Fig. 6F). Additionally,
cranial bone mineralization appeared reduced in Irx3ﬂox/ﬂox/Irx5−/−/
Osx-Cre+ mice, mineralized by 3.5 weeks of age (Supplementary
Fig. 6G-H). Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice whole body bone mineral
density (BMD) were unchanged compared to control littermates but
there was a signiﬁcant decrease in bone mineral content (BMC),
consistent with the reduced bone size (Supplementary Fig. 6I-L). Unfor-
tunately, the high lethality of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice limited
our ability to generate sufﬁcient numbers to adequately analyze the
4 week phenotype further. These data indicate that deletion of Irx3
and Irx5 in osteoblastic cells can inﬂuence both body size and bonemin-
eralization in both newborn and older mice.
2.5. Bone density is reduced in Hamamy syndrome patients
Hamamy patient mutations in IRX5 result in craniofacial
dysmorphisms and mineralization defects while loss of Irx5 in mice
results in no detectable bone abnormalities (Li et al., 2014). Since the
global loss of both Irx3 and Irx5 leads to cardiac phenotypes similar to
those seen in Hamamy patients, wewanted to see if the decreasedmin-
eralization we found in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice also reﬂected
the clinical presentation of Hamamy syndrome patients.
Fig. 5.Mineralization and chondrocyte gene expression is reduced expression in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ calvaria. Relative expression levels of osteoblastic genes (A) Runx2, (B) Osx,
(C) Col1a1, and (D) Bglap. Relative expression levels of chondrogenic genes (E) Sox9, (F) Col2a1, (G) Acan, and (H)Mmp9. Relative expression levels of apoptosis related genes (I) Bcl2 and
(J) Bcl-xl. Relative expression levels of Irx3 and Irx5 related genes (K) Cxcl12 and (L) Trps1. All samples are fromwhole newborn calvaria, n=5 Irx3+/+/Irx5+/+/Osx-Cre−, n=3 Irx3+/+/
Irx5+/+/Osx-Cre+, n = 4 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−, n = 5 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+. Whole calvaria samples were normalized to Irx3+/+/Irx5+/+/Osx-Cre− mice. Statistical
differences were determined by a Student's t-test, *p b 0.05, **p b 0.01, ***p b 0.001. N.S., not signiﬁcant.
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reduced bone mineral density with spine lumbar Z-scores of−3.7 and
−1.5 (Table 1). Bone mineral density improved with age in these
patients to−2.7 and−1.4 at ages 19 and 20 years of age, respectively
(Table 1). The femoral Z-score was determined at 9 years of age for
one Hamamy patient (femoral Z-score of−2.2), but both patients fem-
oral Z-scores remained above−1.0 at 19 and 20 years of age (Table 1).
We noted dramatic reductions in bonemineral content in 3–4week old
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+micewith spontaneous fractures in 3 out of
10mice, indicating that 3–4 week old Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+mice
have similarities to Hamamy patient bonemineralization. Furthermore,
the spontaneous fractures observed in 3–4 week old Irx3ﬂox/ﬂox/Irx5−/−/
Osx-Cre+ mice resembles the bone fragility reported in femora and
other long bones of 8–10 year old Hamamy patients (Hamamy et al.,
2007a).
3. Discussion
Proper craniofacial development requires control of bone minerali-
zation by osteoblastic cell lineages (Mackie et al., 2008; Percival &
Richtsmeier, 2013). Our studies show that osteoblast-speciﬁc loss of
Irx3 and Irx5 leads to impaired mineralization in a very speciﬁc subset
of cranial bones, possibly by blocking their expression of mature
osteoblast mineralization genes (Fig. 7).
During the course of our study, we unexpectedly discovered that
Osx-Cre mice have a newborn mineralization defect independent of
the Irx3 and Irx5mutation status. Our studies are consistent with recent
reports that Osx-Cre mice alone have a newborn bone mineralization
defect, speciﬁcally in intramembranous bones (Wang et al., 2015;
Huang & Olsen, 2015). Interestingly, the absence of both Irx3 and
Irx5 in osteoblastic cells caused an even more dramatic defect in
intramembranous mineralization. Furthermore, Osx-Cre mice can sur-
vive pastweaning and later stages of bonedevelopment occur normally,whereas Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice experience premature
lethality around 3.5–4weeks of agewith bone fragility and spontaneous
fractures. This indicates that the absence of both Irx3 and Irx5 in
osteoblastic cells can inﬂuence neonatal survival at later stages of devel-
opment. Our ﬁndings also emphasize the importance of using Osx-Cre+
littermates as controls for studies involving skeletal development. Fur-
thermore, our results suggest that other Cre drivers, such as Runx2-Cre
or Bglap-Cre mice, may be useful for future studies to conﬁrm early
skeletal mineralization phenotypes (Elefteriou & Yang, 2011).
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice that survive to 3–4 weeks of age
have smaller femora and tibiae and appeared to have signs of bone
fragility, which is consistent with reports of Hamamy syndrome
patients developing bone fragility and long bone fractures later in life
(Hamamy et al., 2007a). Hamamy syndrome patients also had reduced
BMD that was not observed in either newborn or 3–4 week old Irx3ﬂox/
ﬂox/Irx5−/−/Osx-Cre+ mice. BMD measurements in mice are not particu-
larly sensitive and more detailed analysis of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+
bones may be warranted. Our data demonstrate that IRX3 and IRX5 are
important for both early osteoblast mineralization function and later
skeletal mineralization, which also will help in understanding the bone
fragility that occurs in Hamamy patients.
Our use of osteoblast speciﬁc deletion of Irx3 in Irx5−/−mice differs
from previous models that have germ-line deletions of Irx3 and Irx5 or
deletions of Irx1 and Irx2 in chick embryos, all of which showed severe
limb defects (Li et al., 2014; Diaz-Hernandez et al., 2013). We were sur-
prised to ﬁnd that use of the Osx-Cre to delete Irx3 in Irx5−/−mice did
not lead to signiﬁcant limb malformations in newborn Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre+ mice; this is likely due to the fact that endochondral
bone patterning is determined much earlier in development and may
involve a different subset of cell types (Mackie et al., 2008; Knothe
Tate et al., 2008). Furthermore, Irx3 and Irx5 germline deletion resulted
in increased sonic hedgehog signaling sensitivity through upregulation
of Ptc1 and Gli1, which are important for early establishment of limb
Fig. 6. Postnatal Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+mice show reductions in bodyweight and body length. (A) Representative photos of Irx3 and Irx5 genotypes Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−, and
Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice at 3.5 weeks of age. (B) Body weight and (C) body length of 3–4-week-old Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice and littermate controls. Body weight of
(D) 8- and (E) 12-week-old mouse littermate controls, without Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice due to lethality at 4 weeks of age. (F) Ventral, (G) superior, and (H) lateral views of
alizarin red and alcian blue stained Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ and control littermates. Red arrow in (F) denotes spontaneous fracture in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ tibia. 3–4-week
old whole body (I) bone mineral density (BMD) and (J) bone mineral content (BMC) of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ and control littermates. Femur (K) and tibia (L) length from 3 to
4 week old Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ and control littermates. 3–4-week old body weight and length old data is from n= 15 (n= 10 for length measurement) Irx3+/+/Irx5+/+/Osx-
Cre−, n = 10 (n = 9 for length measurement) Irx3+/+/Irx5+/+/Osx-Cre+, n = 15 (n = 12 for length measurement) Irx3+/ﬂox/Irx5+/−/Osx-Cre−, n = 12 (n = 13 for length
measurement) Irx3+/ﬂox/Irx5+/−/Osx-Cre+, n = 3 (n = 3 for length measurement) Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−, and n = 4 (n = 4 for length measurement) Irx3ﬂox/ﬂox/Irx5−/−/Osx-
Cre+ mice. For body mass measurements at 8 and 12 weeks of age, data are from n= 7 Irx3+/+/Irx5+/+/Osx-Cre−, n= 5 Irx3+/+/Irx5+/+/Osx-Cre+, n= 10 Irx3+/ﬂox/Irx5+/−/Osx-Cre−
, n= 7 Irx3+/ﬂox/Irx5+/−/Osx-Cre+, and n= 2 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−mice, pooled sexes. For BMD and BMC, data are from n= 8 Irx3+/+/Irx5+/+/Osx-Cre−, n= 5 Irx3+/+/Irx5+/
+/Osx-Cre+, n= 9 Irx3+/ﬂox/Irx5+/−/Osx-Cre−, n = 8 Irx3+/ﬂox/Irx5+/−/Osx-Cre+, n = 2 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre−mice, and n = 2 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice, pooled sexes.
For femur and tibia measurements, data are from n = 6 (n = 5 for tibia) Irx3+/+/Irx5+/+/Osx-Cre−, n = 6 Irx3+/+/Irx5+/+/Osx-Cre+, n = 5 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre− mice, and
n= 11 Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice, pooled sexes. Statistical differences were determined by a Student's t-test, *p b 0.05, **p b 0.01, ***p b 0.001. N.S., not signiﬁcant.
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Table 1
Hamamy Patient Z-scores.
IRX5 Asn166Lys Patient 1 Patient 2
Age (years) 9 20 8 19
Z-score lumbar spine −1.5 −1.4 −3.7 −2.7
Z-score femoral neck −2.2 Greater than−1 N.D. Greater than−1
93C.J. Cain et al. / Bone Reports 5 (2016) 86–95formation and osteoblast proliferation, but the contribution to the ex-
pression of bone mineralization genes was minimal (Li et al., 2014;
Pan et al., 2013). This further supports the notion that Irx3 and Irx5
play roles in both limb and cranial development, and in cranial and
limb mineralization by osteoblast lineage cells.
While it is clear that IRX3 and IRX5 can regulate cranial bone
mineralization, the mechanism for how IRX3 and IRX5 control bone
mineralization remains unclear. IRX5 might bind to GATA3 and TRPS1
proteins in a complex that regulates cranial neural crest cell migration
(Bonnard et al., 2012). However, our results did not show differential
expression of Cxcl12 (Gaborit et al., 2012), a target of IRX3 and IRX5
which is thought to be regulated by GATA3. In addition, the affected
bones in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice were largely derived from
the mesenchyme, rather than neural crest derivatives. Furthermore,
Trps1 levels were signiﬁcantly reduced in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+
mice suggesting that loss of mineralization is occurring through a
Trps1 speciﬁc pathway (Piscopo et al., 2009). Indeed, previous studies
have shown that murine Irx5 co-immunoprecipitated with Gata3 and
Trps1. When co-immunoprecipitation was done with these proteins
with the Irx5 Asn166Lys mutation, there was markedly less binding to
Trps1 and Gata3, demonstrating that Irx5 binding is reduced by
Hamamy mutations and that Trps1 binding to Irx3 and Irx5 is likely
affected in Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice (Bonnard et al., 2012).
Gata3−/− mice are embryonically lethal from noradrenaline
deﬁciency (Lim et al., 2000) and Gata3−/− rescued embryos display
cranial bone development defects, but Gata3+/− mice appear to have
no bone developmental abnormalities, which suggests that Gata3 is im-
portant for the development of skeletal tissues, but may not be involved
in the regulation of bone mineralization gene expression (Lim et al.,
2000; Pandolﬁ et al., 1995). Unfortunately, the expression of Trps1 has
not been reported in Gata3+/− and Gata3−/− mice (Lim et al., 2000).
Future studies to understand how Trps1 is regulated at speciﬁc stages
of osteoblast mineralization, and if this defect is associated with the
early lethality prior to puberty, will help us to determine the role of
Trps1 in the reduced mineralization of Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+
mice.Fig. 7. Model for the effect of Irx3 and Irx5 on bone mineralization. IRX3 and IRX5 are
required for proximal and anterior limb development and maintain a role in osteoblast
mineralization. In the absence of Irx3 and Irx5 in osteoblast lineage cells, there is a
reduction in osteoblast mineralization, most notably in bones that undergo
intramembranous ossiﬁcation and later in the general skeleton. Osteoblastic cells that
lack IRX3 and IRX5 display reduced Col1a1, Bglap, Mmp9, and Trps1 and there is reduced
bone formation in intramembranous bones, speciﬁcally in the frontal, parietal, and
interparietal bones.Finally, why mice require loss of both IRX3 and IRX5 to develop
reductions in mineralization similar to Hamamy patients who carry a
nonsense mutation in the IRX5 gene remains unclear (Gaborit et al.,
2012). One notion to explain the similar reductions in bonemineraliza-
tion between Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+mice andHamamypatients is
that deletion of both IRX3 and IRX5 in osteoblasts removes the ability to
compensate for the loss of these proteins, whereas Hamamy IRX5 non-
sense mutations inﬂuences IRX3 and IRX5 heterodimer formation and
downstream mineralization function (Gaborit et al., 2012; He et al.,
2009). More detailed analysis of Hamamy syndrome patients cells
using a human induced pluripotent stem cell model may help
demonstrate the dynamics of IRX3 and IRX5 interactions in Hamamy
patient cells.
In conclusion,we identiﬁed a novel role for IRX3 and IRX5 in early cra-
nial mineralization of osteoblastic cells. Furthermore, Irx3ﬂox/ﬂox/Irx5−/−/
Osx-Cre+ mice displayed reduced bone mineralization without affecting
early osteogenic gene expression. Finally, our ﬁnding that Irx3ﬂox/ﬂox/
Irx5−/−/Osx-Cre+ mice have reduced osteoblastic mineralization indi-
cates that IRX3 to IRX5 binding maintains an important role in Hamamy
syndrome and understanding the role of IRX3 and IRX5 together will
help provide insight into the roles of IRX proteins in other organs.
4. Methods
4.1. X-ray analysis of Jordanian and Turkish patients with Hamamy
Syndrome
The Jordanian patients were originally described by HananHamamy
at Jordan University Hospital (Hamamy et al., 2007a). The Turkish
family was diagnosed by Hülya Kayserili at the Medical Genetics
Department of the Istanbul Medical Faculty (Bonnard et al., 2012;
Hamamy et al., 2007a). Both sets of patients provided informed consent
for radiographs to be published, and all studies have been approved by
the local ethic commissions as described (Bonnard et al., 2012). Radio-
graph analysis was done on IRX5 Asn166Lys and IRX5 Ala150Pro
patients and compared to control to assess osteopenia and craniofacial
dysmorphisms. DEXA was used to measure area, BMD, and BMC of the
lumbar spine and femoral neck, and to calculate Z-score. DEXA were
performed just before puberty age (8–9 years old) and at adult age
(19–20 years old).
4.2. Mice
All transgenic mouse studies were approved by and performed in ac-
cordance with the Institutional Animal Care and Use Committee at the
University of California, San Francisco. Irx3ﬂox/ﬂox/Irx5−/−micewere gen-
erated as described (Gaborit et al., 2012). To create tissue speciﬁc Irx3
knockout in osteoblast-lineage cells, we crossed Irx3ﬂox/ﬂox/Irx5−/−
mice with Osx-Cre hemizygous transgenic mice (Jackson Laboratory;
strain: B6·Cg-Tg(Sp7(Osx)-tTA,tetO-EGFP/cre)1Amc/J Jackson ID:
6361) to generate Irx3ﬂox/ﬂox/Irx5−/−/Osx-Cre+ mice (Rodda &
McMahon, 2006).Osx-Cre+ transgenicmicewere found to have early le-
thality (Supplemental Fig. 1C) and a modest newborn bone phenotype
that subsided by 3–4 weeks of age, which has been previously reported
(Wang et al., 2015). We obtained 43% viability of Irx3ﬂox/ﬂox/Irx5−/−/
Osx-Cre+ at birth. Since the Irx3 and Irx5 loci are close together, these
alleles segregate independently only at low frequency (Supplemental
Fig. 1) and so these genotypes were not analyzed. In addition, we
found that Osx-Cre+ mice have a skeletal mineralization deﬁciency at
birth, consistent with recent reports (Wang et al., 2015; Huang &
Olsen, 2015). Thus, all experiments include these mice as a control in
our analyses. For gene expression analysis, breeding pairs of Irx3ﬂox/+/
Irx5+/−/Osx-Cre+ crossed with Irx3ﬂox/+/Irx5+/−/Osx-Cre+ mice were
usedwith no detectable phenotypic differences observed in Osx-Cre sin-
gle and double transgenic mice. All data are from both male and female
mice.
94 C.J. Cain et al. / Bone Reports 5 (2016) 86–954.3. Alizarin red and alcian blue staining of skeletons
Newborn mice and 3–4 week old mice of both sexes were eutha-
nized and prepped for alizarin red and alcian blue skeletal staining
(Ovchinnikov, 2009) by ﬁxing in 100% ethanol for 24 h. Samples were
then switched to acetone (Sigma-Aldrich) for an additional 24 h. Once
ﬁxed, samples were stained with ﬁnal concentration of 5% glacial acetic
acid, 0.5% alizarin red S (Sigma-Aldrich), 0.9% alcian blue 8GX (Sigma-
Aldrich) in ethanol for 3 h at 37 °C and then at room temperature for
24 h. Samples were then placed in 1% KOH (Amresco) for 3 h and
replaced with fresh KOH until non-bone tissue was transparent.
Samples were then replaced with increasing concentrations of glycerol
and photographed with a Leica MZFLIII dissection microscope with
Diagnostic Instruments 14.2 ColorMosaic camera for newborn samples.
3–4 week old samples were photographed with a Nikon E5200without
a microscope.
4.4. Histology
Newborn skulls were skinned and ﬁxed in neutral buffered formalin
for at least 48 h and then replaced with 70% ethanol for at least 24 h.
Skull tissues were parafﬁn embedded and sectioned. Skulls were then
cut at the midline and then stained with hematoxylin & eosin, using
standard protocols (J. David Gladstone Institutes Histology Core).
4.5. Bone densitometry and microCT imaging
DEXAwas used tomeasure mousewhole-body BMD and BMC.Mice
were anesthetized with inhaled isoﬂuorane (1.5% to 2% in oxygen) and
scanned on a GE Lunar Piximus2 (Piximus). Newborn mice that
underwent whole-mouse microCT scans were sacriﬁced and stored in
70% ethanol before scanning. Ex vivo images were obtained on a
Scanco vivaCT-40 microCT scanner (SCANCO) at an X-ray energy of
55kV, with sigma 0.8/support 1/threshold 120 (103.7 mg HA/cm3), a
voxel size of 76 μm, and integration times of 200 ms for whole-body
images.
4.6. RNA isolation, cDNA synthesis, and qPCR
Whole calvaria or dissected calvarial tissues were placed in Trizol
(Invitrogen) and homogenized using a Powergen 125 homogenizer
(Fisher). RNA was isolated using chloroform extraction for whole
calvaria or by Picopure RNA isolation columns for dissected calvaria
(Life Technologies). Puriﬁed mRNAwas then used as a template to syn-
thesize cDNAwith oligo dT primers with the Superscript III (Invitrogen)
kit as described (Cain & Manilay, 2013). qPCR expression analysis was
performed using TaqMan primers for qPCR reactions (Supplementary
Table 1) on a Viia7 real-time thermocycler (Applied Biosystems) run
in 5 μl sample volumes in triplicate or preampliﬁed using Fludigm
preamplication qPCR mix and assayed using Fluidigm dynamic array
IFC qPCR plates (Fludigm). All expression values were normalized to
Gapdh levels.
4.7. Statistics
Differences between the means of biological replicates for all analy-
ses were calculated using two tailed Student's T-test (GraphPad Prism.
La Jolla, CA). Analyses were considered statistically signiﬁcant if p ≤ 0.05.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bonr.2016.02.005.
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